Exempts drug manufacturers and distributors from pharmacist licensing when distributing dialysis drugs to end-stage renal disease patients.

New Jersey A2001 amends pharmacy practice laws to exempt drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs or devices to patients with end-stage renal disease. This exemption applies if the drugs or devices are FDA-approved, held by a properly registered entity, delivered in original, sealed packaging, and only upon a physician's order. Additionally, manufacturers must contract with a registered consultant pharmacist for periodic quality assurance assessments.

Exempts drug manufacturers and distributors from pharmacist licensing when distributing dialysis drugs to end-stage renal disease patients.

New Jersey A2001 amends pharmacy practice laws to exempt drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs or devices to patients with end-stage renal disease. This exemption applies if the drugs or devices are FDA-approved, held by a properly registered entity, delivered in original, sealed packaging, and only upon a physician's order. Additionally, manufacturers must contract with a registered consultant pharmacist for periodic quality assurance assessments.